|Year : 2017 | Volume
| Issue : 3 | Page : 262-268
Cost-of-treatment of clinically stable severe mental lilnesses in India
Siddharth Sarkar1, K Mathan2, Sreekanth Sakey2, Subahani Shaik2, Karthick Subramanian2, Shivanand Kattimani2
1 Department of Psychiatry and NDDTC, All India Institute of Medical Sciences, New Delhi, India
2 Department of Psychiatry, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India
|Date of Web Publication||14-Sep-2017|
Department of Psychiatry and NDDTC, Room no 4096, 4th Floor, Teaching Block, AIIMS, Ansari Nagar, New Delhi
Source of Support: None, Conflict of Interest: None
Background and Aims: The cost-of-treatment studies can help to make informed decisions while planning health-care services. This study is aimed to assess direct costs of outpatient treatment of four common chronic severe mental illnesses in a tertiary care hospital in South India. Methods: The patients with ICD-10 diagnoses of schizophrenia, unspecified nonorganic psychosis, bipolar disorder, and recurrent depression were recruited by purposive sampling from a government teaching hospital in South India. The total cost-of-treatment to the patient and the hospital was computed for each disorder as a percentage of the per-capita income of an individual patient. Results: The study comprised a total of 140 patients. The average monthly total cost-of-treatment was Indian Rupees (INR) 770 (95% confidence interval of 725 to 815), or approximately US$ 12.8. The monthly total cost-of-treatment was INR 720 for schizophrenia, INR 750 for unspecified nonorganic psychosis, INR 830 for bipolar disorder, and INR 790 for recurrent depression, with no significant differences between groups. On an average, 22.8% of total cost-of-treatment was borne by the patient, and the rest by the hospital. The patients spent a median of 12% of their per-capita income on treatment related to direct costs. Conclusions: Despite substantial government subsidies, patients do incur some expenses in treatment of chronic psychiatric illnesses. The attempts to reduce treatment and travel costs can facilitate psychiatric care to larger number of individuals.
Keywords: Bipolar disorder, cost of treatment, depression, psychosis, schizophrenia
|How to cite this article:|
Sarkar S, Mathan K, Sakey S, Shaik S, Subramanian K, Kattimani S. Cost-of-treatment of clinically stable severe mental lilnesses in India. Indian J Soc Psychiatry 2017;33:262-8
|How to cite this URL:|
Sarkar S, Mathan K, Sakey S, Shaik S, Subramanian K, Kattimani S. Cost-of-treatment of clinically stable severe mental lilnesses in India. Indian J Soc Psychiatry [serial online] 2017 [cited 2020 Jun 6];33:262-8. Available from: http://www.indjsp.org/text.asp?2017/33/3/262/214600
| Introduction|| |
The cost-of-treatment is an important issue while making informed choices about provision of psychiatric treatment services., When the resources are limited, it becomes incumbent upon health-care providers to ensure access to care to as many individuals as possible. Hence, there is a need to find the costs associated with various treatment options. However, health care costs can be computed in a variety of ways. The direct costs refer to costs incurred by the patients and other agencies for medications, hospital visits and hospitalization. The indirect costs involve intangible expenses like loss of income from work and societal costs. Though direct costs are tangible and can be clearly elucidated, indirect costs are relatively difficult to be uniformly applied, and vary across health systems.,
Marked differences are present between developed and developing countries with respect to the structure of service provision, actual service utilization and the economic impact of psychiatric disorders., The studies about cost-of-treatment of psychiatric disorders are relatively fewer from India, an emerging and populous developing country.,,, Further, no study has attempted to explicitly compare the cost-of-treatment to the financial background of the patient population. Hence, this study was conducted to assess the cost of treatment of four severe mental illnesses, which require long term psychotropic medication, and to compare it with the per-capita income of the patient.
| Materials and Methods|| |
Setting of the study
The study was conducted in a multi-specialty governmental teaching hospital in South India, which provides both inpatient and outpatient psychiatric services. The patients are either referred from other centers/departments, or are self-referred. A diagnosis is made in accordance with ICD 10 after detailed assessment and discussion with consultant. Regular follow-ups are advised as a part of treatment of chronic psychiatric disorders. The family members usually accompany the patients to the clinic. The hospital primarily caters to patients from lower socio-economic strata. There is no consultation fee for seeking treatment at the centre, and many medications are provided free from the hospital pharmacy, typically for 3 weeks at a time.
The present study included outpatients with an ICD 10 diagnosis of schizophrenia (F20), unspecified nonorganic psychosis (psychosis NOS) (F29), bipolar affective disorder (BPAD) (F31), and recurrent depressive disorder (RDD) (F33), of more than 1 year duration and on stable doses of medication for last 3 months. In case, if the patient had a relapse in the last 1 year, but were on stable doses of medication in the last 3 months, they were included. The patients with a diagnosis of current substance dependence (apart from nicotine), mental retardation, or organic psychiatric disorders were excluded. The participants were recruited after obtaining informed consent and the study had Institutional Ethics Committee approval. The data collection was done between March 2014 to June 2014.
The information was gathered from the patients, their caregivers' medical records, and in a single sitting using a structured questionnaire. The data was obtained about the basic demographic details, diagnosis, duration of illness and treatment, current treatment regimen, per-capita family income, and amount spent per-month on travel related to treatment. In cases of irregular family income, the participant was asked to provide an estimate of the average monthly income for the year.
The cost calculations were done in Indian Rupees (INR) per month, and rounded off to the nearest 10 (1 US Dollar was approximately equivalent to INR 60 at the time of the study). For the purposes of the study, the direct cost-of-treatment was sub-divided into cost to the patient and cost to the hospital. The cost to patient included money spent on travel and medication purchased from outside the hospital. Medications were prescribed from outside either because; the medications available from inside the hospital were intolerable or were proved ineffective. The cost to the hospital was computed by adding the cost of services and infrastructure (hospital consultation estimate) to the hospital pharmacy medication costs.
The costs of medication for each patient were calculated by obtaining the median current market costs of medication as per current drug review. The monthly cost-of-treatment at the median prescribed dose was calculated for each of the medications for representation. A single strength of dosing was available for medications available in the hospital pharmacy to minimize prescription and dispensing errors. For bulk purchases, it is possible that hospital could obtain significant discounts. Hence, additional analyses were conducted with medication cost discounted at 25% and 50%. But still, drug review estimates were used and not the current hospital actual procurement costs, as hospital procurement costs may vary markedly from year to year based upon sealed competitive bidding. For providing an international perspective, the monthly costs of each medication in USA were also enumerated.
The hospital consultation estimate was calculated by adding the cost of service (salaries in weighted proportion of the time spent in the outpatient services) and the cost of hospital infrastructure (approximate amount payable for renting the outpatient area, electricity charges, furniture and other incidentals). The total monthly expense per-month was divided by the number of distinct patients seen per-month to arrive at the hospital consultation estimate per-patient per-month. The hospital consultation estimate was based on simplistic assumption that all patients required roughly equal amount of time per month, irrespective of their diagnosis; though it is possible that different patients required different amount of consultation time. An alternate analysis was also conducted with an increase in the cost of hospital consultation estimate by 20% to account for possible inflated incidentals like procurement costs, possible investigations, differences in cost of medications at different outlets etc. The base year for the comparisons was 2014.
The demographic and clinical characteristics of the patients were descriptively represented across the different diagnostic groups. The costs of treatment (both to the patient and the hospital) were calculated for the diagnostic sub-groups. Non-parametric tests were used for comparison of clinical and cost characteristics due to skewed data.
Thereafter, proportion of the per-capita income spent by the patient towards treatment (travel and outside medication) was computed. This was done to assess the burden of the treatment on the patients and their families despite attending to a ‘free’ government hospital. The proportion was dichotomized on the cut-off of 100% of per-capita income (i.e. spending one person of the family's entire monthly expenses towards treatment).
| Results|| |
Patient characteristics and medications
The study included 140 patients across 4 diagnostic groups (32 with schizophrenia, 52 with psychosis NOS, 40 with BPAD and 16 with RDD). The distribution of the patients in the different diagnostic groups is shown in [Table 1]. The mean monthly per-capita family income was INR 1680. The four groups differed from each other on duration of illness (p = 0.010), duration of treatment (p = 0.012), and number of pills taken per day (p = 0.002).
The psychotropic medications prescribed to entire set of patients are listed in [Table 2]. Only 16 out of 140 patients (11.4% of the sample) were prescribed medications from outside the hospital. Risperidone, fluoxetine and valproate were the most commonly prescribed antipsychotic, antidepressant and mood-stabilizer medications, respectively. Diazepam was the most commonly prescribed sedative-hypnotic. About 47.9% of the sample was on 3 or more medications, while none of the patients were prescribed 5 or more medications. For the total sample, antipsychotics contributed to 36.4% of total psychotropic medication cost, mood stabilizers to 21.3%, sedative-hypnotics to 15.9%, antidepressants to 11.8%, and other medications contributed to 14.6% of the total medication costs.
On an average, the total monthly direct cost of treatment was INR 770 per patient (95% confidence interval of 725 to 815). The average monthly medication cost-per-patient was INR 390, out of which 87.9% was borne by the hospital pharmacy. The monthly hospital consultation estimate was calculated to be INR 260 per-patient per-month. The treatment costs for various disorders are depicted in [Table 3]. The hospital pharmacy medication costs differed significantly between the diagnostic groups, leading to difference in costs to the hospital (Kruskal Wallis χ2 = 9.303, p = 0.026 for both). The cost to the hospital was 29.6%, 24.1% and 1.8% higher for RDD, BPAD and schizophrenia group than patients with psychosis NOS. The costs of treatment are graphically depicted in [Figure 1].
|Figure 1: BPAD Bipolar Affective Disorder, INR Indian Rupees, RDD Recurrent Depressive Disorder|
Click here to view
On an average, 22.8% of the costs were borne by the patient. The proportion of total cost of treatment borne by the hospital to the total cost was calculated to estimate the subsidy provided. The degree of subsidy ranged from 72.0% for treatment of psychosis NOS, 75.3% for the treatment of schizophrenia, 79.8% for BPAD, and 88.6% for the treatment of RDD (average subsidy of 77.2% for all the disorders combined).
Treatment costs as a proportion of per-capita income
Next, treatment costs were calculated as a percentage of per-capita income. This was done to find out the financial burden posed by the treatment on the income of the patient and their family. The patients currently spend a median of 12% (inter-quartile range [IQR] of 4% to 26.7%) of their per-capita income on treatment related expenses. However, it was seen that 4.0% of the sample spent more than 100% of the per-capita income on treatment related expenses.
That total treatment costs comprised a median of 71.1% (IQR of 31.7% to 133.2%) of the monthly per-capita income of patient. The total treatment costs surpassed the per-capita monthly income in 32.3% of the patients. The percentage of per-capita income spent on treatment is graphically represented in [Figure 1]. It did not significantly differ across the treatment groups (Kruskal Wallis χ2 = 3.192, p = 0.363).
Analysis with discounted medication costs and inflated hospital consultation estimate
An alternate analysis with discounted medication prices (at discount rates of 25% and 50%, respectively) brought down the monthly cost of treatment per patient to INR 690 and INR 600 (decrement of 10.9% and 21.8%, respectively in the monthly total costs of treatment). Similarly, an increase in the hospital consultation estimate by 20% increased the cost of monthly cost of treatment to INR 820, reflecting an increase of 6.7% in the cost of treatment per patient.
Discounting of prices of medication and escalation of hospital consultation estimate did not have an impact on the percentage of per-capita income spent by the patients. But discounting of 25% and 50% of medication costs, the cost to the hospital reduced the median total costs-of-treatment from 71.1% of per-capita income of the patient to 63.8% and 54.5% of the per-capita income (reduction of 7.3% and 16.6%, respectively). Similarly, escalation of hospital consultation estimate by 20% increased the median total cost-of-treatment as percentage of per-capita income to 75.0% (increase of 3.9%).
| Discussion|| |
Patient and medication characteristics
The present analysis was conducted in a group of outpatient at a tertiary care hospital on relatively stable doses of medication. The study had a higher representation of patients with a diagnosis of psychosis NOS as compared to schizophrenia. Other prescription audits from India also suggest that patients with unspecified psychosis might outnumber schizophrenia, probably because of restrictive diagnostic criteria of schizophrenia as per ICD 10. The mean monthly per-capita income of the sample was INR 1680 (annual per-capita income of approximately US$335). This was considerably lower than current per-capita GDP of India of US$1499, suggesting that a large number of treatment seekers to this hospital belonged to lower socio-economic status. On an average, patients were prescribed 2 to 3 types of psychotropic medication. This is similar to office based prescriptions from elsewhere.
The type of medications being commonly prescribed was based upon constraints of hospital supply and therapist preferences. Risperidone was the second-generation antipsychotic available free of cost from the hospital, and was the commonest prescribed antipsychotic according to the survey of prescription patterns among Indian psychiatrists. The use of antidepressants fluoxetine and amitriptyline was not in line with the prescription pattern from other places of India, and escitalopram seems to be most commonly prescribed antidepressant in the region. A larger proportion of patients rely on valproate as mood-stabilizer rather than lithium, due to physician preferences. Another study from north India has also found similar prescribing trends of valproate eclipsing lithium.
It is interesting to note that the monthly medication costs were considerably lower in India as compared to USA. This was primarily so for the antipsychotics, especially the newer antipsychotics. Taking risperidone as an example, the cost of monthly supply of this medication in USA was 13.4 times that of India (4 times higher after correcting for purchasing power parity [PPP] of 2013). The monthly cost of aripiprazole was about 85.2 times higher in USA after correcting for PPP. However, for some medications like fluoxetine and lithium, medication costs in the US were only 2.9 and 2.1 times higher, respectively (0.86 and 0.61 times after correcting for PPP), after matching the medications costs in India.
Costs of treatment
The present study suggests that direct monthly cost of treatment of a stable patient with severe psychiatric disorder at the centre was INR 770, roughly translating to US$ 12.8 per month or US$ 154 annually. The direct cost per patient was higher than two previous studies,, probably accounted by inflation over time. However, it was interesting to see that monthly medication costs have not increased substantially over a period of time. The present study takes into consideration the costs borne for the consultation, which is likely to vary from place to place and can be considerable. The resources spent by the hospital and other service provider can be substantial and may be more than cost of medications.,, In our study, the proportion of costs borne by healthcare provider was higher than a north Indian study, probably because a larger proportion of patients got free medications from the hospital in the present sample.
The direct costs of treatment in this study was found to be lower than Europe; other developed countries like Australia, Canada and USA; and other developed Asian countries;, though differences in ascertainment methodology may be remarked. The lower costs of treatment in the present setting might be ascribed to two factors. Firstly, the medication costs in India had been comparatively lower than certain other western countries due to policies of the Indian government,, which made effective medications accessible to the Indian masses at affordable costs. Secondly, the cost of services in healthcare sector in India has been comparatively lower than Western countries. However, it must be remarked that the monthly cost of treatment was found to be higher than reported from other developing countries like Nigeria and Sri Lanka.,
On a macroeconomic level, the cost of treatment of patients who are maintaining well on psychotropic medication can be massive when computed for the entire Indian population. Taking conservative estimates, if 2% of the adult population has severe psychiatric illness requiring treatment, of which only 25% are treated, and of them 20% (i.e. 5% of population with severe mental illness) at government hospitals, it would translate to 720,000 individuals. The direct governmental cost of treatment of these ‘well’ individuals would be approximately 665 crore INR.
Comparison to per-capita incomes
The patients spent a median of 12% of their per-capita income on treatment. But a small proportion (4.0%) spent more than 100% of their per-capita income on treatment. This suggests a potentially unsustainable financial scenario, predisposing to treatment non-adherence. It has been seen that high cost of treatment could be an important predictor of non-adherence in clinical population in India and elsewhere.,, Also, it must be acknowledged that despite treatment at the hospital being ‘free', patients needed to incur some direct expenses, especially for travel and at times for medication. To reduce costs of treatment borne by the patient further, steps can be taken including giving free bus passes, providing medication for a longer time, and providing home based treatment. Tele-psychiatry can also be attempted for delivering expert treatment services through the primary health care centers.
The study also further analyzed percentage of per-capita income, which would be used up if government subsidy did not exist. In the absence of subsidy, the median per-capita income spent on treatment would increase from 12% to 71.1% (increase of about 600%), which would be a great financial burden to the patients and their families. This would push the direct treatment spending of more than 30% of the patients above 100% of their per-capita income. Such an increase is likely to further lead to difficulty to continue medications, leading to relapses and further increase in the direct and indirect costs associated with the illness. Hence, government funding needs to be continued for the treatment services.
Strengths and limitations
The findings of the study should be interpreted in the light of strengths and limitations. The strengths of the study include comparison of four chronic and severe psychiatric disorders encountered in clinical psychiatric practice. The study estimated the proportion of per-capita income of the patient being spent on treatment, in an attempt to understand the burden of treatment costs on the patient and the family. Additional analyses were carried out by factoringin the effect of discounted medication prices and escalating consultation costs.
The limitations of the study include purposive sampling leading to selection bias, reliance on self-report for income and travel expenses, and estimation of medication prices based upon rates quoted in drug indices. Systematic scales were not used to measure severity of different disorders. Disability benefits, if received were not factored into the calculations. The results reflect findings from one government teaching hospital and generalization is constrained by varied staffing patterns, hospital policies, and clientele in different institutions. The present study did not include costs of treatment of other comorbid disorders, and costs incurred on nutraceuticals/ investigations. The study refrained from computing indirect costs encompassing cost of care giving, loss of income, cost of alternate treatments, and costs to law enforcement requirement ascribed to psychiatric illness. It was stratified by the socio-economic status, residence and other demographic characteristics, as data on these aspects could not be gathered accurately in the present set-up. Cost estimations may be carried in a variety of ways and the methods used in the present study represent one of the ways. Formal sample size estimation was not done for this study
To conclude, the present descriptive study suggests that monthly direct cost of outpatient treatment for psychiatric disorders in India is approximately INR 770, out of which 22.8% was spent by the patient on medications and travel expenses, and 77.2% was spent by the hospital. Clinical practice may be enriched by careful consideration of the cost of extraneous medications and frequency of visits, especially for patients belonging to lower socio-economic status. Further studies may delve into the cost of treatment of other psychiatric disorders like substance use disorders and comorbid disorders like diabetes. The studies assessing cost of treatment in different settings nationally or internationally using similar methodology can help in a better comparative analysis.
| Acknowledgements|| |
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Gustavsson A, Svensson M, Jacobi F, Allgulander C. Alonso J, Beghi E, et al.
Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011;21:718-79.
Fineberg NA, Haddad PM, Carpenter L, Gannon B, Sharpe R, Young AH, et al.
The size, burden and cost of disorders of the brain in the UK. J Psychopharmacol 2013;27:761-70.
Akobundu E, Ju J, Blatt L, Mullins CD. Cost-of-illness studies : a review of current methods. PharmacoEconomics 2006;24:869-90.
Awad AG, Voruganti LNP. The burden of schizophrenia on caregivers: a review. PharmacoEconomics 2008;26:149-62.
Rössler W, Salize HJ, van Os J, Riecher-Rössler A. Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol 2005;15:399-409.
Kawakami N, Abdulghani EA, Alonso J, Bromet EJ, Bruffaerts R, Caldas-de-Almeida JM. Early-life mental disorders and adult household income in the World Mental Health Surveys. Biol Psychiatry 2012;72:228-37.
Gadit AA. Out-of-Pocket expenditure for depression among patients attending private community psychiatric clinics in Pakistan. J Ment Health Policy Econ 2004;7:23-8.
Grover S, Avasthi A, Chakrabarti S, Bhansali A, Kulhara P. Cost of care of schizophrenia: a study of Indian out-patient attenders. Acta Psychiatr Scand 2005;112:54-63.
Sharma P, Das SK, Deshpande SN. An estimate of the monthly cost of two major mental disorders in an Indian metropolis. Indian J Psychiatry 2006;48:143-8.
] [Full text]
Somaiya M, Grover S, Avasthi A, Chakrabarti S. Changes in cost of treating schizophrenia: comparison of two studies done a decade apart. Psychiatry Res 2014;215:547-53.
Sarma GP, General hospital psychiatry: cost of one visit. Indian J Psychiatry 2000;42:258-61.
Current index of medical stores (CIMS). Delhi: Sanjay and Company; 2013.
Prices, coupons and information - GoodRx [Internet]. Available from: http://www.goodrx.com
. [cited 2014 Jul 29].
Grover S, Kumar V, Avasthi A, Kulhara P. An audit of first prescription of new patients attending a psychiatry walk-in-clinic in north India. Indian J Pharmacol 2012;44:319-25. [Full text]
Mojtabai R, Olfson M. National trends in psychotropic medication polypharmacy in office-based psychiatry. Arch Gen Psychiatry 2010;67:26-36.
Grover S, Avasthi A. Anti-psychotic prescription pattern: A preliminary survey of Psychiatrists in India. Indian J Psychiatry 2010;52:257-9.
] [Full text]
Grover S, Avasth A, Kalita K, Dalal PK, Rao GP, Chadda RK. et al.
IPS multicentric study: Antidepressant prescription patterns. Indian J Psychiatry 2013;55:41-5.
] [Full text]
Srinivasa Murthy R, Kishore Kumar KV, Chisholm D, Thomas T, Sekar K, Chandrashekari CR. Community outreach for untreated schizophrenia in rural India: a follow-up study of symptoms, disability, family burden and costs. Psychol Med 2005;35:341-51.
Chisholm D, Sekar K, Kumar KK, Saeed K, James S, Mubbashar M. et al.
Integration of mental health care into primary care. Demonstration cost-outcome study in India and Pakistan. Br J Psychiatry 2000;176:581-8.
Knapp M, Mangalore R, Simon J. The global costs of schizophrenia. Schizophr Bull 2004;30:279-93.
Lee IH, Chen PS, Yang YK, Liao YC, Lee YD, Yeh TL. et al.
The functionality and economic costs of outpatients with schizophrenia in Taiwan. Psychiatry Res 2008;158:306-15.
Law WL, Hui HY, Young WM, You JHS. A typical antipsychotic therapy for treatment of schizophrenia in Hong Kong Chinese patients–a cost analysis. Int J Clin Pharmacol Ther 2007;45:264-70.
Rangnekar D. No pills for poor people? Understanding the disembowelment of India's patent regime. Econ PolitWkly 2006;409-17.
Sampath PG, India's Product Patent Protection Regime: Less or More of “Pills for the Poor”? J World Intellect Prop 2006;9:694-26.
Suleiman TG, Ohaeri JU, Lawal RA, Haruna AY, Orija OB. Financial cost of treating out-patients with schizophrenia in Nigeria. Br J Psychiatry 1997;171:364-8.
De Silva J, Hanwella R, de Silva VA. Direct and indirect cost of schizophrenia in outpatients treated in a tertiary care psychiatry unit. Ceylon Med J 2012;57:14-8.
Kessler RC, Aguilar-Gaxiola S, Alonso J, Chatterji S, Lee S, Ormel J. et al.
The global burden of mental disorders: an update from the WHO World Mental Health (WMH) surveys. Epidemiol Psichiatr Soc 2009;18:23-33.
Sitholey P, Agarwal V, Chamoli S. A preliminary study of factors affecting adherence to medication in clinic children with attention-deficit/hyperactivity disorder. Indian J Psychiatry 2011;53:41-4.
] [Full text]
Piette JD, Heisler M, Wagner TH. Cost-related medication underuse: do patients with chronic illnesses tell their doctors? Arch Intern Med 2004;164:1749-55.
Wagner MM, Blackorby J. Transition from high school to work or college: how special education students fare. Future Child 1996;6:103-20.
Chavan BS, Tyagi S, Gupta N. Home based treatment: A community outreach service for engaging the non-engagers. Indian J Soc Psychiatry 2013;29:A10.
[Table 1], [Table 2], [Table 3]
|This article has been cited by|
Medication Profile and Treatment Cost Estimation Among Outpatients with Schizophrenia, Bipolar Disorder, Depression, and Anxiety Disorders in Indonesia
| ||Irma Melyani Puspitasari,Rano Kurnia Sinuraya,Cherry Rahayu,Witriani Witriani,Uzlifatul Zannah,Auliani Hafifah,Ajeng Ratna Ningtyas,Hilda Vildayanti |
| ||Neuropsychiatric Disease and Treatment. 2020; Volume 16: 815 |
|[Pubmed] | [DOI]|
||Pharmacotherapeutic interventions for bipolar disorder type II: addressing multiple symptoms and approaches with a particular emphasis on strategies in lower and middle-income countries
| ||Brian Godman,Christoffel Grobler,Marianne Van-De-Lisle,Janney Wale,Wallace Breno Barbosa,Amos Massele,Philip Opondo,Guenka Petrova,Konstantin Tachkov,Israel Sefah,Suhaj Abdulsalim,Alian A. Alrasheedy,Mazhuvancherry Kesavan Unnikrishnan,Kristina Garuoliene,Kayode Bamitale,Dan Kibuule,Francis Kalemeera,Joseph Fadare,Tanveer Ahmed Khan,Shahzad Hussain,Tomasz Bochenek,Aubrey Chichonyi Kalungia,James Mwanza,Antony P Martin,Ruaraidh Hill,Corrado Barbui |
| ||Expert Opinion on Pharmacotherapy. 2019; 20(18): 2237 |
|[Pubmed] | [DOI]|
||Impact of community-based rehabilitation for mental illness on ‘out of pocket’ expenditure in rural South India
| ||Thanapal Sivakumar |
| ||Asian Journal of Psychiatry. 2019; |
|[Pubmed] | [DOI]|
||Disability and socio-economic impact of mental disorders in the state of Punjab, India: Findings from national mental health survey, 2015–2016
| ||BS Chavan,Subhash Das,Rohit Garg,Sonia Puri,Aravind BA Banavaram |
| ||International Journal of Social Psychiatry. 2018; 64(6): 589 |
|[Pubmed] | [DOI]|